section name header

Indications

REMS

Samsca:

Jynarque:

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: palpitations.

Derm: dry skin, rash.

Endo: hyperglycemia.

F and E: thirst, hypernatremia, hypovolemia.

GI: constipation, diarrhea, dry mouth, appetite, dyspepsia, HEPATOTOXICITY.

GU: polyuria.

Metab: hyperuricemia.

Neuro: dizziness, weakness, osmotic demyelination.
Misc: (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

Samsca and Jynarque should not be used interchangeably

Hyponatremia (Samsca)

Autosomal Dominant Polycystic Kidney Disease (Jynarque and Jinarc)

US Brand Names

Jynarque, Samsca

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: electrolyte modifiers

Pharmacologic Classification: vasopressin antagonists

Pharmacokinetics

Absorption: 40% absorbed following oral administration.

Distribution: Well distributed to tissues.

Protein Binding: >99%.

Metabolism/Excretion: Extensively metabolized in the liver via the CYP3A4 isoenzyme; 59% excreted in the feces (19% as unchanged drug), with 40% excreted in the urine (<1% as unchanged drug).

Half-life: 12 hr.

Canadian Brand Names

Jinarc

Time/Action Profile

ROUTEONSETPEAKDURATION
POwithin 8 hr2–4 hr7 days

† Plasma concentrations.

Patient/Family Teaching

Pronunciation

tol-VAP-tan